Ipswich Spine Clinic Receives Rave Reviews for its Transformative Chiropractic Care
Committed to revitalize the age-old treatment technique, Ipswich Spine embodies a patient-centric strategy.SUFFOLK, UK / ACCESSWIRE / August 17, 2023...
Brain
Sartorius and Repligen Corporation Launch Integrated System with Biostat STR® and XCell® ATF for Upstream Process Intensification
Biostat STR(R) Bioreactor Biostat STR® now contains a fully compatible embedded XCell® ATF hardware and software moduleBioreactor and cell retention...
Napo Pharmaceuticals Surveys of Neurologists, Patients, and Caregivers Regarding Amyotrophic Lateral Sclerosis (ALS) Treatment Indicate Real World Burden of Diarrhea and Potential Treatment Interruption
Jaguar Health family company Napo Pharmaceuticals focuses on essential supportive care and management of neglected toxicities in multiple complicated disease...
Helius Medical Technologies Announces Reverse Stock Split
NEWTOWN, Pa., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company...
Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience
Day One receives an exclusive license to develop and commercialize small molecule drug candidates for pediatric and adult cancers with...
FSD Pharma Selected to Present its Phase 1 Data on Lucid-MS at MSMilan 2023 – 9th Joint ECTRIMS-ACTRIMS Meeting for October 11-13, 2023
Targeting the Approximate $22 Billion Multiple Sclerosis Drug Treatment MarketTORONTO, ON / ACCESSWIRE / August 15, 2023 / FSD Pharma...
NeurAxis Announces Positive University of Michigan IB-Stim™ Cost Effectiveness Study at ANMS 2023
CARMEL, Ind., Aug. 15, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company...
Microbot Medical Boosts Manufacturing and Commercialization Capabilities for its Robotic Surgical System
The Agreement with a leading full turnkey manufacturer further strengthens the Company's progression towards expected first in human clinical trials...
Aruna Bio Announces Oral Presentation on Treatment Opportunities of Lead Program, AB126 at the Exosome Based Therapeutic Development Summit and Applications of Exosomes BioProcess International Conference & Exhibition
- AB126 is an unmodified exosome derived from neural stem cells with the innate ability to cross the blood-brain-barrier and...
Autism: Is This a Vascular Disease and Would Therapeutic Angiogenesis Be a Potential Treatment?
LAS VEGAS, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Dr. Jack Jacobs, Chief Science Officer of Zhittya Genesis Medicine, Inc. (a...
Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive Refund
MELBOURNE, Australia and SAN FRANCISCO, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or...
Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease
Foralumab to advance into Phase 2 human clinical trials using the world’s only fully human intranasal anti-CD3 monoclonal antibodyTrial to...
Freeline Reports Second Quarter 2023 Financial Results and Business Highlights
Completed dosing in first cohort of Phase 1/2 GALILEO-1 trial of FLT201 in Gaucher disease; expect to report initial clinical...
VA Boston Healthcare Implements Palarum SmartSock Technology to Prevent Patient Falls
BOSTON, MA / ACCESSWIRE / August 15, 2023 / The VA Boston Healthcare System has implemented the Palarum® PUP® SmartSock...
Zion Healing Inc. Announces $25 Million Private Placement to Fund Innovative Veterans Initiative
SAINT GEORGE, UT / ACCESSWIRE / August 14, 2023 / Zion Healing Inc. and its subsidiary, Zion Healing Development Company,...
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
Data presented at the 2023 SNO/ASCO CNS Cancer ConferenceBerubicin currently being evaluated in an ongoing potentially pivotal study for the...
Halberd-Mississippi State University (MSU) Testing of TBI Nasal Spray Progresses
Scientific Paper Presented at Research SymposiumJACKSON CENTER, PA / ACCESSWIRE / August 14, 2023 / Halberd Corporation's (OTC PINK:HALB) Traumatic...
CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming Milestones
Continued rapid pace of enrollment with ~75% of expected patients now enrolled in ongoing potentially pivotal study evaluating Berubicin for...
Ketabon GmbH Reports Top-Line Results from Phase 2 Trial of Take-at-Home, Oral Ketamine Option for Treatment-Resistant Depression
Lead Asset KET01, an Oral Prolonged-Release Ketamine Formulation, Demonstrated Early Improvements in Depressive Severity Key Findings Included Minimal Incidences of...
Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Phase 1/2a SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024...